Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314026 · ClinicalTrials.gov registry record · Phase 2
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
A Phase 2 study, sponsored by Meridian Bioscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT02314026: Completed Phase 2 study, sponsored by Meridian Bioscience.
NCT02314026 is a Phase 2 study that has completed, run by Meridian Bioscience. The registered enrollment target is 140 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02314026, a Phase 2 study, has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study's aim is to develop an algorithm for the ¹³C-Octanoate Breath Test with or without the ¹³C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histological findings associated with of Non-Alcoholic Steatohepatitis (NASH) and other liver diseases using the BreathID® System
Primary Outcome
Non-Alcoholic Steatohepatitis (NASH) as determined by liver biopsy histology will be the comparator
Interventions
- DEVICE Suspected NASH BreathID test with 13C-Octanoate
- DEVICE Suspected NASH Breath test with 13C Methacetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02314026 record still lists
NCT02314026 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Suspected NASH BreathID test with 13C-Octanoate is the first listed.
NCT02314026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02314026 about?
NCT02314026 is a clinical study titled "BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH". This study's aim is to develop an algorithm for the ¹³C-Octanoate Breath Test with or without the ¹³C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histological findings associated with of Non-Alcoholic Steatohepatitis (NASH) and other liver diseases using the BreathID® Syst...
What is the current status of trial NCT02314026?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2015-03. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02314026?
The interventions under investigation include: Suspected NASH BreathID test with 13C-Octanoate (DEVICE), Suspected NASH Breath test with 13C Methacetin (DEVICE).
Who is sponsoring clinical trial NCT02314026?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02314026's enrollment target sits among peer trials
140 512th of 2000 higher than 1,476 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia